Femasys Inc. (NASDAQ: FEMY) has partnered with UNC Health to integrate its portfolio of fertility diagnostic and treatment solutions into the healthcare system's obstetrics and gynecology practices. The collaboration was announced at the American College of Obstetricians and Gynecologists (ACOG) Annual Clinical and Scientific Meeting on May 1, with the objective of advancing earlier fertility evaluation and intervention within patient care pathways.
Under the agreement, UNC Health will incorporate Femasys' products, including FemVue, an ultrasound-based assessment tool for Fallopian tube patency in women, and SpermVue, a home-based male fertility screening kit. Additionally, FemaSeed Complete, an in-office intratubary insemination solution, will be made available as a first-line fertility treatment option. The solution combines FemaSeed with FemSperm for in-office sperm preparation and handling.
UNC Health, North Carolina's largest academic healthcare system, operates hospitals, clinics, and physician offices across the state. Dr. John Jack Coiner II, a physician at UNC Health, highlighted the geographic challenges faced by patients in the High Country region, where travel times to fertility specialists can exceed several hours. The integration of these technologies aims to reduce delays in diagnosis and treatment by enabling earlier intervention before specialist referrals.
Femasys also noted progress on its non-surgical permanent birth control solution, FemBloc, which is currently in a pivotal clinical study. The company previously secured regulatory approvals for FemBloc in Europe, the United Kingdom, and New Zealand in 2025, positioning it for potential broader market access pending further clinical and regulatory developments.
